International WELL Building Institute Opens Enrollment for WELL Health-Safety Rating In Response to COVID-19 With Significant Early Adoption
8.7.2020 20:18:00 EEST | Business Wire | Press release
The International WELL Building Institute (IWBI) announced that enrollment has opened today for the WELL Health-Safety Rating for Facility Operations and Management, with more than 100 organizations and real estate portfolios across the globe already enrolled. Organizations across a wide range of industries and geographic locations have responded swiftly to implement the program’s science-backed guidance as they seek to instill confidence and trust among their staff, stakeholders and the broader community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005768/en/
The WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing building and space types focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prepare their spaces for re-entry in a post COVID-19 environment.
Adapted from features in the WELL Building Standard (WELL) that focus on facilities, maintenance and operations, the WELL Health-Safety Rating is designed to guide and empower the actions of large and small businesses alike in taking the necessary steps to prioritize the health and safety of their staff, visitors and stakeholders. It also serves as an annual process that supports efforts to promote the long-term health and safety of people.
“We’re all eager to get back to our workplaces, back to school, back to traveling, dining, and cheering on our favorite teams and performers,” said IWBI Chairman and CEO Rick Fedrizzi. “As organizations across the globe respond to the COVID-19 crisis through changes in policies and protocols, the WELL Health-Safety Rating delivers the evidence-based health strategies required to help them safely reopen with the confidence and integrity provided by third-party verification.”
Created by IWBI, the WELL Health-Safety Rating is informed by guidance developed by the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), global disease control and prevention centers and emergency management agencies, recognized standard-making bodies, such as ASTM International and ASHRAE, and leading academic and research institutions. IWBI has leveraged insights from its Task Force on COVID-19, established at the outset of the pandemic to help business and building leaders integrate actionable insights and proven strategies in the fight against COVID-19 and other respiratory infections.
“This moment has highlighted the critical role that buildings, and those that own and operate them, can play in supporting people’s health, safety and well-being,” said IWBI President Rachel Gutter. “This new rating aims to meet the urgent need to deliver high health and safety standards in all of the spaces we occupy. While longer term design strategies are important in reducing the risks of infectious disease spread, this rating focuses on strategies that can be implemented immediately to address acute threats, using our buildings and spaces as a first line of defense in the fight against COVID-19.”
Demonstrating thought leadership and commitment to the health and safety of their stakeholder communities, the following leading organizations are among the first that have enrolled to achieve the WELL Health-Safety Rating:
|
ACCIONA SA |
|
Adventist Health |
|
Aedifica |
|
Alpin Limited (Masdar City) |
|
American Savings Bank |
|
Bartra Capital Property |
|
CAMCO Management Co. |
|
Carrier |
|
Catalyst Partners |
|
CBD Z03 |
|
CBRE Barcelona |
|
CBRE Madrid |
|
China Overseas Office Capital |
|
Cleveland Clinic Courts / Cleveland Cavaliers |
|
Climate Change Arena |
|
Community Investment Strategies, Inc |
|
CR Land |
|
Deerns |
|
Delos China |
|
Delos Living LLC |
|
Delta Electronics, Inc. |
|
Denholtz Properties |
|
Department of Earth System Science, Tsinghua University |
|
Empire State Realty Trust |
|
EMSI |
|
GFP Real Estate |
|
Ghelamco Poland Sp. z o.o. |
|
Glenstar |
|
GuocoLand China Ltd. |
|
HBMSU |
|
Heitman |
|
Herman Miller Group |
|
Hornets Sports & Entertainment - Spectrum Center |
|
HRO |
|
Infancix Co., Ltd |
|
International Commerce Centre |
|
International WELL Building Institute PBC |
|
Ivanhoé Cambridge |
|
Jiahui Health |
|
JLL |
|
Karisma Hotels and Resorts |
|
Kilroy Realty Corporation |
|
Kimball |
|
Laguna |
|
Lendlease Australia Office Portfolios: Australian Prime Property Fund Commercial, Lendlease International Towers Sydney Trust and Lendlease One International Towers Sydney Trust |
|
Lincoln Property Company |
|
M Moser Associates |
|
Mace |
|
Maple Leaf Sports & Entertainment (MLSE), which encompasses the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto FC (MLS), & Toronto Argonauts (CFL) |
|
Menarco Development Corporation |
|
Milliken & Company |
|
ML7 |
|
Montage International |
|
Moody Center
|
|
New Belmont Arena |
|
New York Yankees |
|
Oak View Group |
|
Out of the Box Ventures |
|
Overbury Morgan Lovell |
|
OVG Arena Alliance & Stadium Alliance |
|
OVG Facilities |
|
Pacers Sports & Entertainment: Bankers Life Fieldhouse (Indianapolis, Ind.) |
|
Pacers Sports & Entertainment: St. Vincent Center/Indiana Pacers Training Facility (Indianapolis, Ind.) |
|
Parmenter Realty Partners |
|
Phipps Conservatory and Botanical Gardens |
|
RMZ Corp |
|
Rocket Mortgage FieldHouse / Cleveland Cavaliers & Cleveland Monsters |
|
Royal Albert Hall |
|
Rubrik India Pvt Ltd |
|
Savanna |
|
Serpentini Auto Group |
|
Shanghai Landleaf Architecture Technology Co. Ltd |
|
ShouGang Group |
|
Sino-Ocean |
|
Space Matrix Design Consultants Pvt. Ltd
|
|
TAIPEI 101 Tower |
|
Taiwan Architecture & Building Center |
|
Teknion |
|
The Florida Panthers and BB&T Center |
|
The Forestias |
|
The Related Group |
|
Thornton Tomasetti |
|
TITANIUM OFFICE SOLUTIONS MEXICO |
|
Uber Technologies, Inc. |
|
UltraStar Harrah’s Ak Chin Resort Maricopa, Az. |
|
United Center |
|
Webster Bank Arena |
|
Wells Fargo Center, Philadelphia, Pa. |
|
Wolfgang Puck Fine Dining Group |
|
Woonerf Inc. |
|
Yuexiu Commercial |
Upon achieving the designation, IWBI will issue the building or space a WELL Health-Safety seal.
The WELL Health-Safety Rating draws on principles established by IWBI’s WELL Building Standard, the premier standard for healthy real estate, which has surpassed 590 million square feet in registrations across 62 countries since inception. The WELL Building movement has been further amplified by over 12,000 WELL Accredited Professionals (APs) and registrants across the globe.
To learn more about the WELL Health-Safety Rating and to enroll, please visit www.wellcertified.com/health-safety.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005768/en/
Contact information
Media:
Judith Webb
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
